RE:RE:RE:Proph. the manipulatorPBaelishh wrote: Nothing is de-risked as long as the biggest risk remains: GILLES GAGNON.
That's been demonstrated with his tenure at AEZS as the CEO where the share price has dropped 80%, and more recently when he joined the board in 2020 where the share price dropped 96% (including a 1 for 25 share rollback) to where it is now.
His failures in running CEAPRO have been well documented here. As we are calling the board to remove him from the CEO seat, he is circumventing all this by making himself the CEO of a merged company where he will have a friendly board and where he was the CEO before.
As was posted in mid 2020 when we heard Gilles joined the board of AEZS, the nightmare is here, what was stated back is much more relevant now, esp. seeing how AEZS has been an destroyer of shareholder value. Gilles failure to monetize PGX commercially is his fault. We have the AV phase 1/2a due in 9 months, positive results if "marketed" could bring in commercial interests and an opportunity to raise capital. Yes, a capable CEO would be able to captialize on the disruptive tech of PGX.
July 2020 post No doubt that when I first heard that Gilles joined AEZS in January that I believed he wanted to fast track CZO onto NASDAQ. However, keep in mind that AEZS was losing its eligibility based on its share price, and now trading under $1 with the impact of the financing, the timing isn't there now, but could be there later. A COVID 19 treatment would be a gold mine, I wouldn't want to see a "non-arms length" deal. Hopefully with a PGX deal / human trials on the COVID 19 therapeutic around December, we shall see CZO at a much higher cap. Perhaps in mid to late 2021, CZO could merge with AEZS to get a NASDAQ listing, though I don't think it would be that urgent if CZO is successful in H2 2020 with their pipeline. Keep in mind that results on the BG pill will be out in H2 2021. I'd rather see CZO remain solo that dilute itself with what I percieve is a much weaker, one product,much lower potential company.